Press releases
- Aurigene Pharmaceutical Services Limited, a Global CRDMO, Announces the Opening of Its Biologics Facility Offering Process Development and Clinical Scale Manufacturing Capabilities
- Dr. Reddy's Laboratories Announces the Appointment of Milan Kalawadia to CEO North America
- Alvotech and Dr. Reddy’s Enter Into Collaboration for Commercialization of AVT03 (denosumab), a Biosimilar Candidate to Prolia® & Xgeva® in the U.S., Europe and UK
- Dr. Reddy’s Q4 & Full Year FY24 Financial Results
- Dr. Reddy's Laboratories Announces the Launch of Doxycycline Capsules, 40 mg* in the U.S.
- Dr. Reddy's Laboratories launches Versavo® (bevacizumab) in the UK
More ▼
Key statistics
On Friday, Dr Reddy's Laboratories Ltd (RDDA:MUN) closed at 64.50, -10.42% below its 52-week high of 72.00, set on Feb 29, 2024.
52-week range
Open | 64.50 |
---|---|
High | 64.50 |
Low | 64.50 |
Bid | 65.50 |
Offer | 66.50 |
Previous close | 64.50 |
Average volume | 86.67 |
---|---|
Shares outstanding | 166.53m |
Free float | 166.00m |
P/E (TTM) | 17.27 |
Market cap | 11.54bn USD |
EPS (TTM) | 4.02 USD |
Annual div (ADY) | 0.435 EUR |
---|---|
Annual div yield (ADY) | 0.68% |
Div ex-date | Jul 28 2023 |
Div pay-date | Aug 11 2023 |
Data delayed at least 15 minutes, as of Jun 07 2024 07:05 BST.
More ▼